Treatment with biosimilar drug improves progression-free survival in breast cancer pa

[News]

Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to a study published online by JAMA.

More... (http://www.news-medical.net/news/20161201/Treatment-with-biosimilar-drug-improves-progression-free-survival-in-breast-cancer-patients.aspx)